Dear Sir/Madam:

The Food and Drug Administration acknowledges receipt of the following Drug Master File (DMF) submission:

**DMF Number Assigned:** 18920  **Date of Submission:** December 9, 2005

**DMF Type:** III

**Title of Submission:** Polyvinyl Chloride (PVC) Raw Material Grade Reon 5711 as manufactured in Gujarat, India

**Holder of Submission:** Reliance Industries Limited

**Submitted by:** Reliance Industries Limited

**Agent(s):** None

All subsequent correspondence to this DMF should be identified with the information as provided above. Submissions to the DMF should be forwarded in duplicate.

Your DMF will be reviewed only in connection with the New Drug Applications, Abbreviated New Drug Applications, Investigational New Drug Applications or any DMFs it is intended to support.

The holder of the DMF is responsible for compliance with the Regulation Title 21 Code of Federal Regulations Part 314.420 as interpreted in “The Guideline for Drug Master Files” [HEW (FDA) 79-3072. www.fda.gov/cder/guidance/dmf.htm. You are expected to:

- Adhere to the statement of the commitment you have provided
- Provide to the FDA by submission to the DMF in two copies:
  - an annual update of the DMF containing:
    - a list of all changes and additional information incorporated into the DMF since the previous annual report on the subject matter of the DMF. If the subject matter of the DMF is unchanged, provide a statement that the subject matter of the DMF is current. Note that the annual update is not intended for reporting changes to the DMF. Such changes should be reported as separate amendments.

    - a list of all persons authorized to make reference to the DMF, identifying by name (or code) the information that each person
is authorized to incorporate and give the location of that information by date, volume, and page number. If the list is unchanged on the anniversary date, submit a statement that the list is current.

- identification of any party whose authorization has been withdrawn

- any change or addition to the technical information, adequately cross-referenced to the date(s), volume(s), section(s), and/or page number(s) affected.

- any change in authorization related to specific customers

- any change in holder name or ownership of the DMF or a change in the agent name or address. Such changes should be reported as separate amendments.

Sincerely,

Scott E. Lemon
Sharon L. Brownewell
Public Health Analyst
Manager of Drug Master Files
Office of Information Management
Records Repository Team

CC: ChronDMF 18920 Orig., Dup.